A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer. (OReO)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03106987 |
Recruitment Status :
Completed
First Posted : April 11, 2017
Results First Posted : April 19, 2022
Last Update Posted : October 7, 2022
|
Sponsor:
AstraZeneca
Collaborator:
European Network of Gynaecological Oncological Trial Groups (ENGOT)
Information provided by (Responsible Party):
AstraZeneca
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Double (Participant, Investigator); Primary Purpose: Treatment |
Condition |
Epithelial Ovarian Cancer |
Interventions |
Drug: Active Comparator: Olaparib tablets Drug: Placebo |
Enrollment | 220 |
Participant Flow
Recruitment Details | This study was conducted at study centres in 11 countries (France, Italy, Spain, Germany, Poland, Belgium, Denmark, Israel, United Kingdom, Norway, and Canada) between 8-Jun-2017 and 15-Feb-2021. |
Pre-assignment Details | Patients were randomised into 1 of 2 cohorts depending on their known BRCA1/2 status (BRCA1/2 +ve or BRCA1/2-ve). Within each cohort, patients were randomised in a 2 Olaparib:1 placebo ratio. Randomisation was stratified by prior use of bevacizumab and number of prior regimens of platinum-containing chemotherapy. |
Arm/Group Title | Olaparib (BRCA1/2 +ve) | Placebo (BRCA1/2 +ve) | Olaparib (BRCA1/2 -ve) | Placebo (BRCA1/2 -ve) |
---|---|---|---|---|
Arm/Group Description | Patients received olaparib 300mg tablets orally twice daily (bd) continuously | Patients received placebo 300mg tablets administered orally twice daily (bd) continuously | Patients received olaparib 300mg tablets orally twice daily (bd) continuously | Patients received placebo 300mg tablets administered orally twice daily (bd) continuously |
Period Title: Overall Study | ||||
Started | 74 | 38 | 72 | 36 |
Completed | 30 | 15 | 54 | 25 |
Not Completed | 44 | 23 | 18 | 11 |
Reason Not Completed | ||||
Death | 37 | 22 | 12 | 8 |
Lost to Follow-up | 2 | 0 | 2 | 2 |
Withdrawal by Subject | 5 | 1 | 4 | 1 |
Baseline Characteristics
Arm/Group Title | Olaparib (BRCA1/2 +ve) | Placebo (BRCA +ve) | Olaparib (BRCA1/2 -ve) | Placebo (BRCA 1/2 -ve) | Total | |
---|---|---|---|---|---|---|
Arm/Group Description | Patients received olaparib 300mg tablets orally twice daily (bd) continuously | Patients received placebo 300mg tablets administered orally twice daily (bd) continuously | Patients received olaparib 300mg tablets orally twice daily (bd) continuously | Patients received placebo 300mg tablets administered orally twice daily (bd) continuously | Total of all reporting groups | |
Overall Number of Baseline Participants | 74 | 38 | 72 | 36 | 220 | |
Baseline Analysis Population Description |
Full analysis set (FAS) consisted of all randomised patients analysed on an intent-to-treat (ITT) basis.
|
|||||
Age, Continuous
Mean (Standard Deviation) Unit of measure: Years |
||||||
Number Analyzed | 74 participants | 38 participants | 72 participants | 36 participants | 220 participants | |
59.2 (9.31) | 61.5 (9.22) | 64.2 (9.64) | 63.3 (9.05) | 61.9 (9.54) | ||
Age, Customized
Measure Type: Count of Participants Unit of measure: Participants |
||||||
Number Analyzed | 74 participants | 38 participants | 72 participants | 36 participants | 220 participants | |
< 50 |
11 14.9%
|
3 7.9%
|
4 5.6%
|
1 2.8%
|
19 8.6%
|
|
≥ 50 to < 65 |
40 54.1%
|
20 52.6%
|
29 40.3%
|
19 52.8%
|
108 49.1%
|
|
≥ 65 to < 75 |
20 27.0%
|
12 31.6%
|
30 41.7%
|
11 30.6%
|
73 33.2%
|
|
≥ 75 |
3 4.1%
|
3 7.9%
|
9 12.5%
|
5 13.9%
|
20 9.1%
|
|
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
||||||
Number Analyzed | 74 participants | 38 participants | 72 participants | 36 participants | 220 participants | |
Female |
74 100.0%
|
38 100.0%
|
72 100.0%
|
36 100.0%
|
220 100.0%
|
|
Male |
0 0.0%
|
0 0.0%
|
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Race/Ethnicity, Customized
Measure Type: Count of Participants Unit of measure: Participants |
||||||
Number Analyzed | 74 participants | 38 participants | 72 participants | 36 participants | 220 participants | |
White |
71 95.9%
|
35 92.1%
|
66 91.7%
|
33 91.7%
|
205 93.2%
|
|
American Indian or Alaska Native |
0 0.0%
|
0 0.0%
|
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Asian |
0 0.0%
|
0 0.0%
|
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Black or African American |
0 0.0%
|
0 0.0%
|
1 1.4%
|
0 0.0%
|
1 0.5%
|
|
Hawaiian Native or Other Pacific Islander |
0 0.0%
|
0 0.0%
|
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Other |
3 4.1%
|
3 7.9%
|
5 6.9%
|
2 5.6%
|
13 5.9%
|
|
Missing Data |
0 0.0%
|
0 0.0%
|
0 0.0%
|
1 2.8%
|
1 0.5%
|
Outcome Measures
Adverse Events
Limitations and Caveats
[Not Specified]
More Information
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts
the PI's rights to discuss or publish trial results after the trial is completed.
No unpublished information may be disclosed without prior written approval from AstraZeneca.
Results Point of Contact
Name/Title: | Global Clinical Head |
Organization: | AstraZeneca Clinical Study Information Center |
Phone: | 1-877-240-94 79 |
EMail: | information.center@astrazeneca.com |
Responsible Party: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT03106987 |
Other Study ID Numbers: |
D0816C00014 |
First Submitted: | March 24, 2017 |
First Posted: | April 11, 2017 |
Results First Submitted: | February 15, 2022 |
Results First Posted: | April 19, 2022 |
Last Update Posted: | October 7, 2022 |